Efficacy of 1-Year Cavacurmin® Therapy in Reducing Prostate Growth in Men Suffering from Lower Urinary Tract Symptoms

We aim to assess the effect of Cavacurmin(R) on prostate volume (PV), lower urinary tract symptoms (LUTS) and micturition parameters in men after 1 year of therapy. From September 2020 to October 2021, data from 20 men with LUTS/benign prostatic hyperplasia and PV >= 40 mL who were on therapy with alpha 1-adrenoceptor antagonists plus Cavacurmin((R)) were retrospectively compared with 20 men on only alpha 1-adrenoceptor antagonists. Patients were evaluated at baseline and after 1 year using the International Prostate Symptom Score (IPSS), prostate-specific antigen (PSA), maximum urinary flow (Qmax) and PV. A Mann-Whitney U-test and Chi-square were used to assess the difference between the two groups. A comparison of paired data was performed with the Wilcoxon signed-rank test. Statistical significance was set at p-value < 0.05. There was no statistically significant difference in baseline characteristics between the two groups. At the 1-year follow-up, PV [55.0 (15.0) vs. 62.5 (18.0) mL, p = 0.04)], PSA [2.5 (1.5) ng/mL vs. 3.05 (2.7) vs. p = 0.009] and IPSS [13.5 (3.75) vs. 18 (9.25) p = 0.009] were significantly lower in the Cavacurmin(R) group. Qmax was significantly higher in the Cavacurmin((R)) group [15.85 (2.9) vs. 14.5 (4.2), p = 0.022]. PV was reduced to 2 (5.75) mL in the Cavacurmin((R)) group from baseline, while it increased to 12 (6.75) mL in the alpha 1-adrenoceptor antagonists group (p < 0.001). PSA decreased in the Cavacurmin((R)) group [-0.45 (0.55) ng/mL], whereas it increased in the alpha 1-adrenoceptor antagonists group [0.5 (0.30) ng/mL, p < 0.001]. In conclusion, one-year Cavacurmin((R)) therapy was able to block prostate growth with a concomitant decrease in PSA value from baseline. The association of Cavacurmin((R)) with alpha 1-adrenoceptor antagonists had a more beneficial effect compared to patients on alpha 1-adrenoceptor antagonists alone but this needs further larger studies to be confirmed, particularly in the long-term.

Automated summary

The study aimed to evaluate the impact of Cavacurmin(R) on prostate volume (PV), lower urinary tract symptoms (LUTS), and micturition parameters in men after 1 year of therapy. The retrospective comparison of 20 men receiving alpha 1-adrenoceptor antagonists plus Cavacurmin(R) with 20 men receiving only alpha 1-adrenoceptor antagonists revealed that the combination therapy led to significantly lower PV, PSA, and IPSS levels, as well as higher Qmax values.